- United States
- /
- Life Sciences
- /
- NasdaqGS:SEER
Newsflash: Seer, Inc. (NASDAQ:SEER) Analysts Have Been Trimming Their Revenue Forecasts
Today is shaping up negative for Seer, Inc. (NASDAQ:SEER) shareholders, with the analysts delivering a substantial negative revision to next year's forecasts. Revenue estimates were cut sharply as analysts signalled a weaker outlook - perhaps a sign that investors should temper their expectations as well.
After this downgrade, Seer's three analysts are now forecasting revenues of US$20m in 2024. This would be a huge 21% improvement in sales compared to the last 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$28m in 2024. The consensus view seems to have become more pessimistic on Seer, noting the pretty serious reduction to revenue estimates in this update.
See our latest analysis for Seer
Of course, another way to look at these forecasts is to place them into context against the industry itself. We would highlight that Seer's revenue growth is expected to slow, with the forecast 17% annualised growth rate until the end of 2024 being well below the historical 62% p.a. growth over the last five years. By way of comparison, the other companies in this industry with analyst coverage are forecast to grow their revenue at 3.7% annually. So it's pretty clear that, while Seer's revenue growth is expected to slow, it's still expected to grow faster than the industry itself.
The Bottom Line
The most important thing to take away is that analysts cut their revenue estimates for next year. They're also forecasting more rapid revenue growth than the wider market. Overall, given the drastic downgrade to next year's forecasts, we'd be feeling a little more wary of Seer going forwards.
Still got questions? We have estimates for Seer from its three analysts out until 2025, and you can see them free on our platform here.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqGS:SEER
Seer
A life sciences company, engages in developing and commercializing products to decode the biology of the proteome.
Flawless balance sheet with limited growth.